Trial reportBMC surgery2025
Effects of different doses of remimazolam besylate on postoperative sedation, pain, and adverse reactions in patients undergoing hysteroscopic surgery.
Trial report in BMC surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effects of Remimazolam Dose and Bolus Injection Rate on Hiccups During Painless Colonoscopy: A Double-Blind Randomized Clinical Trial.Drug design, development and therapy · 2026Trial
- What Is the Most Effective Strategy for Acute Postoperative Pain in Total Knee Arthroplasty-Retrospective Observational Study.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHysteroscopy, a minimally invasive gynecological procedure, requires effective sedation for patient comfort and surgical success. Remimazolam Besylate, a new ultra-short-acting benzodiazepine, offers potential for safe sedation, but the optimal dose for postoperative outcomes is unclear. This study evaluated the effects of different doses of Remimazolam Besylate on postoperative sedation, pain, and adverse reactions in hysteroscopic surgery patients.
methodsFrom June 2020 to June 2022, 90 patients undergoing hysteroscopic surgery under general anesthesia were randomly divided into three subgroups (A, B, C; n = 30 each). Subgroup A received 0.2 mg/kg, Subgroup B received 0.3 mg/kg, and Subgroup C received 0.4 mg/kg of Remimazolam Besylate intravenously during anesthesia induction. Postoperative outcomes, including pain stress mediators (PGE2 and 5-HT), Pain Visual Analogue Scale (VAS) scores, Ramsay Sedation scores, and adverse events, were compared among the subgroups.
resultsSubgroup A (0.2 mg/kg) showed significantly higher levels of PGE2 and 5-HT at 2, 12, and 24 h postoperatively compared to Subgroups B (0.3 mg/kg) and C (0.4 mg/kg). VAS scores at 2 and 12 h were higher in Subgroup A, while Ramsay Sedation scores were lower. Subgroup C had a significantly higher incidence of adverse reactions compared to Subgroups A and B.
conclusionRemimazolam Besylate at a dose of 0.3 mg/kg is optimal for anesthesia induction in hysteroscopic surgery, providing effective sedation, reduced postoperative pain, and a lower incidence of adverse reactions compared to higher doses. This dose is recommended for achieving balanced sedation and safety outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.